Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anusha Thomas

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Expert Opinion on Drug Safety|February 10, 2026
Rare irAes associated with immune checkpoint inhibitor therapyJarrett Rong, Faraz Jafri, Sean Ngo, et al.
Expert Opinion on Drug Safety|April 17, 2026
Refractory immune-related adverse events (irAes) associated with immune checkpoint inhibitor therapy: a multiorgan management reviewMaria Julia Moura, Anirudha Chatterjee, Sharada Wali, et al.
Gastrointestinal Endoscopy|January 25, 2024
Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patientsYinghong Wang, Hamzah Abu-Sbeih, Tenglong Tang, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Expert Opinion on Drug Safety|February 10, 2026
Rare irAes associated with immune checkpoint inhibitor therapyJarrett Rong, Faraz Jafri, Sean Ngo, et al.
Expert Opinion on Drug Safety|April 17, 2026
Refractory immune-related adverse events (irAes) associated with immune checkpoint inhibitor therapy: a multiorgan management reviewMaria Julia Moura, Anirudha Chatterjee, Sharada Wali, et al.
Gastrointestinal Endoscopy|January 25, 2024
Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patientsYinghong Wang, Hamzah Abu-Sbeih, Tenglong Tang, et al.
Pageof 3